PharmaEssentia Corporation (TPE:6446)
Taiwan flag Taiwan · Delayed Price · Currency is TWD
536.00
+6.00 (1.13%)
Apr 2, 2025, 1:30 PM CST

PharmaEssentia Company Description

PharmaEssentia Corporation, a biopharmaceutical company engages in treatment for human diseases in Taiwan and internationally.

Its products include Ropeginterferon alfa-2b that is used for the treatment of chronic myelogenous leukemia, T-Cell leukemia, early myelofibrosis, polycythemia vera, and essential thrombocythemia.

The company also develops TCRT, anti PD-1, PEG-cytokine X,Y, and novel checkpoint abs for the treatment of solid tumors; P1101 + anti PD-1 for the treatment of hepatocellular carcinoma; and PEG-GCSF for the treatment of neutropenia.

In addition, it focuses on the drug research and development programs in the areas of hematology, infectious disease, and oncology.

PharmaEssentia Corporation was founded in 1990 and is headquartered in Taipei, Taiwan.

PharmaEssentia Corporation
Country Taiwan
Founded 1990
Industry Drug Manufacturers - Specialty & Generic
Sector Healthcare
Employees 131
CEO Ko-Chung Lin

Contact Details

Address:
No. 3, Park Street
Taipei, 115
Taiwan
Phone 886 2 2655 7688
Website pharmaessentia.com

Stock Details

Ticker Symbol 6446
Exchange Taiwan Stock Exchange
Fiscal Year January - December
Reporting Currency TWD
ISIN Number TW0006446008
SIC Code 2836

Key Executives

Name Position
Ko-Chung Lin Ph.D. Founder, Chief Executive Officer, Chief Strategy Officer and Director
Chan-Kou Hwang Ph.D. President, GM and Director
Snow Chang Director of Finance
Samuel Lin Vice President and Head of Business Operations and Strategy
Lih-Ling Lin Ph.D. Chief Scientific Officer
Dr. Albert Qin M.D., Ph.D. Chief Medical Officer
Narihisa Miyachi Head of Japan Medical Affairs
Yen-Tung Luan Chief Operating Officer of Taichung Plant
Wu Kuo-Hsiung Chief of Taichung Plant
Jason Mitch Vice President and Head of Market Access